Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD
In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.
Pfizer Has Launched PfizerForAll, an Online Multipronged Direct-to-Consumer Service
PfizerForAll offers telehealth and prescription services, vaccination scheduling and savings programs, and is partnering with recognized companies such as InstaCart.
FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults
The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.
COPD Outcomes: Sedentary Lifestyle Significantly Increases Risk for ED Visits, Hospitalization
Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.
